The implications and consequences of these actions and subsequent actions by the Trump Administration to compel an MFN regulatory pricing requirement in the U.S. and otherwise advance drug pricing policy continue to remain unclear and uncertain and this lack of clarity or the adoption of policies regarding pricing could adversely affect our business.
